![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SLC5A12 |
Gene summary for SLC5A12 |
![]() |
Gene information | Species | Human | Gene symbol | SLC5A12 | Gene ID | 159963 |
Gene name | solute carrier family 5 member 12 | |
Gene Alias | SMCT2 | |
Cytomap | 11p14.2 | |
Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | Q1EHB4 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
159963 | SLC5A12 | HTA11_6801_2000001011 | Human | Colorectum | SER | 1.85e-04 | 3.29e-01 | 0.0171 |
159963 | SLC5A12 | HTA11_7696_3000711011 | Human | Colorectum | AD | 9.56e-07 | 1.84e-01 | 0.0674 |
159963 | SLC5A12 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 1.38e-30 | 6.55e-01 | 0.3005 |
159963 | SLC5A12 | HCC1_Meng | Human | Liver | HCC | 1.17e-29 | 1.21e-01 | 0.0246 |
159963 | SLC5A12 | HCC1 | Human | Liver | HCC | 3.12e-03 | 2.49e+00 | 0.5336 |
159963 | SLC5A12 | HCC2 | Human | Liver | HCC | 5.93e-12 | 2.43e+00 | 0.5341 |
159963 | SLC5A12 | HCC5 | Human | Liver | HCC | 5.65e-04 | 2.47e-01 | 0.4932 |
159963 | SLC5A12 | S014 | Human | Liver | HCC | 3.54e-04 | 1.40e-01 | 0.2254 |
159963 | SLC5A12 | S016 | Human | Liver | HCC | 1.12e-03 | 1.34e-01 | 0.2243 |
Page: 1 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SLC5A12 | SNV | Missense_Mutation | c.151N>T | p.Gly51Cys | p.G51C | Q1EHB4 | protein_coding | tolerated(0.09) | probably_damaging(0.984) | TCGA-A8-A08L-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
SLC5A12 | SNV | Missense_Mutation | novel | c.68N>A | p.Gly23Glu | p.G23E | Q1EHB4 | protein_coding | deleterious(0.02) | possibly_damaging(0.459) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SLC5A12 | SNV | Missense_Mutation | novel | c.823G>A | p.Ala275Thr | p.A275T | Q1EHB4 | protein_coding | deleterious(0) | probably_damaging(0.968) | TCGA-BH-A0BJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
SLC5A12 | SNV | Missense_Mutation | novel | c.888C>G | p.Ile296Met | p.I296M | Q1EHB4 | protein_coding | deleterious(0.01) | possibly_damaging(0.653) | TCGA-BH-A5J0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SLC5A12 | SNV | Missense_Mutation | c.1319N>T | p.Gly440Val | p.G440V | Q1EHB4 | protein_coding | tolerated(0.68) | benign(0.012) | TCGA-E2-A1LH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
SLC5A12 | SNV | Missense_Mutation | novel | c.1237N>A | p.His413Asn | p.H413N | Q1EHB4 | protein_coding | tolerated(0.11) | benign(0.043) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
SLC5A12 | SNV | Missense_Mutation | c.15C>G | p.Asn5Lys | p.N5K | Q1EHB4 | protein_coding | tolerated(0.15) | benign(0.001) | TCGA-ZJ-AAXI-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD | |
SLC5A12 | SNV | Missense_Mutation | c.1675N>C | p.Cys559Arg | p.C559R | Q1EHB4 | protein_coding | deleterious(0.02) | benign(0.001) | TCGA-A6-5665-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
SLC5A12 | SNV | Missense_Mutation | rs760908310 | c.721A>G | p.Ile241Val | p.I241V | Q1EHB4 | protein_coding | tolerated(0.09) | benign(0.075) | TCGA-AA-3811-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
SLC5A12 | SNV | Missense_Mutation | c.724A>C | p.Thr242Pro | p.T242P | Q1EHB4 | protein_coding | deleterious(0.01) | benign(0.251) | TCGA-AA-A01P-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |